Herbert Irving Comprehensive Cancer Center
Investigator
Matthew Ingham, MD
Phone
212-305-7115
Email
mi2337@cumc.columbia.edu
Dr. Ingham is Assistant Professor of Medicine in the Division of Hematology and Oncology at New York Presbyterian Hospital/Columbia University Medical Center. He received his medical degree from the University of Massachusetts Medical School and completed internship and residency training in Internal Medicine at New York University Medical Center, where he served as Chief Resident. He then completed fellowship training in Hematology and Medical Oncology at New York Presbyterian Hospital/Columbia University Medical Center where he served as Chief Fellow.

Dr. Ingham specializes in the care of patients with sarcoma and gastrointestinal cancers and is also an active member of the experimental therapeutics unit. His research focuses on the development and clinical evaluation of new treatments for patients with sarcoma. He leads a National Cancer Institute (NCI) sponsored clinical trial evaluating a new treatment approach for uterine leiomyosarcoma based on research conducted at Columbia University. He also leads several other investigator-initiated clinical trials evaluating new targeted and immunotherapy based treatment approaches for leiomyosarcoma, liposarcoma and other types of sarcoma. He is the author of two recent authoritative reviews on the treatment of sarcoma published in the Journal of Clinical Oncology. He is the recipient of the 2019 Conquer Cancer Foundation of ASCO Career Development Award from the Sarcoma Foundation of America in recognition of his research and was also named a 2019 NextGen Innovator by HemOnc Today, among other awards and honors. His overall goal is to provide patients with compassionate oncologic care and access to the most promising treatment approaches.

Clinical Studies Managed By This Investigator:
Condition Study Title
Cancer [ CLOSED ] A study for patients with AML, MDS, Myelofibrosis or solid tumors using study drug INCB059872
Cancer [ CLOSED ] A study for patients with sarcoma using study drug MGCD516
Cancer [ CLOSED ] A study for patients with advanced solid tumors or lymphomas using study drug MK-1454
Cancer Collecting and growing patient tumor and blood cells from extra tissue to learn about cancer and test new drugs
Gastrointestinal [ CLOSED ] INVICTUS Study of Drug in Advanced Gastrointestinal Stromal Tumors
Cancer Early Onset Malignancies Initiative (EOMI)
Cancer Study of Drug (MK-2118) in Patients with Solid Tumors or Lymphomas
Cancer [ CLOSED ] Study of MIW815 (ADU-S100) in Patients with Advanced/Metastatic Solid Tumors or Lymphomas
Sarcoma [ CLOSED ] A Study of AL3818 (Anlotinib) in Patients with Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma
Sarcoma A Study of the Addition of APX005M to Doxorubicin in Patients with Advanced Sarcoma
Solid Tumors [ CLOSED ] A Study of BA3021 in Patients with Advanced Solid Tumors (Lung Cancer, Triple Negative Breast Cancer, or Soft Tissue Sarcoma)
Sarcoma A Study of PTC596 in Combination With Dacarbazine in Participants With Advanced Leiomyosarcoma (LMS)
Sarcoma [ CLOSED ] Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma
Sarcoma [ CLOSED ] Study of Talimogene Laherparepvec (T-VEC) and Radiation in Soft Tissue Sarcoma
Cancer [ CLOSED ] Genetic Analysis of Blood and Tissue Samples From Participants With Advanced Cancer
Cancer [ CLOSED ] Study of Intratumorally Administered INT230-6 in Adult Subjects with Solid Tumors
Gynecologic Cancer [ CLOSED ] Study of Olaparib in Combination with Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma
Cancer Study of BA3011 in Subjects with Advanced Solid Tumors
Sarcoma [ CLOSED ] Tazemetostat in Combination With Doxorubicin as Therapy for Advanced Epithelioid Sarcoma
Cancer [ CLOSED ] Study Evaluating BI 1387446 Alone and in Combination with BI 754091 in Solid Tumors
Sarcoma Study of Belinostat and Guadecitabine for Treatment of Chondrosarcoma
Cancer A First-in-Human Study of CDK-002 (exoSTING) in Subjects with Advanced/Metastatic Solid Tumors
Cancer A Study of ASP9801 in Patients With Advanced Metastatic Solid Tumors
Sarcoma Study of ATX-101 in Patients with Dedifferentiated Liposarcoma (LPS) and Leiomyosarcoma (LMS)
Sarcoma Study of INBRX 109 in Patients with Metastatic or Inoperable Chondrosarcoma
Cancer Study of GSK3901961 and GSK3845097 in Patients with Synovial Sarcoma or Non-Small Cell Lung Cancer (NSCLC)
Sarcoma Study of Unesbulin in Patients with Leiomyosarcoma (LMS)